Cargando…

Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review

The coronavirus disease-2019 (COVID-19) pandemic continues to challenge health care systems around the world. Scientists and pharmaceutical companies have promptly responded by advancing potential therapeutics into clinical trials at an exponential rate. Initial encouraging results have been realize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Horani, Rami A., Kar, Srabani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600245/ https://www.ncbi.nlm.nih.gov/pubmed/32993173 http://dx.doi.org/10.3390/v12101092

Ejemplares similares

Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials
por: Al-Horani, Rami A., et al.
Publicado: (2020)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle
por: Huynh, Trang T. X., et al.
Publicado: (2023)

Ethacrynic acid is an inhibitor of human factor XIIIa
por: Kar, Srabani, et al.
Publicado: (2022)

Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa
por: Kar, Srabani, et al.
Publicado: (2021)

Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase
por: Al-Horani, Rami A., et al.
Publicado: (2021)

Sulphated penta-galloyl glucopyranoside (SPGG) is glycosaminoglycan mimetic allosteric inhibitor of cathepsin G
por: Al-Horani, Rami A, et al.
Publicado: (2023)

Isobavachalcone inhibits post-entry stages of the porcine reproductive and respiratory syndrome virus life cycle
por: Wang, Hai-Ming, et al.
Publicado: (2018)

Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2
por: Chen, Irene P., et al.
Publicado: (2022)

Impact of Comorbidities on SARS-CoV-2 Viral Entry-Related Genes
por: Breidenbach, Joshua D., et al.
Publicado: (2020)

Trypsin enhances SARS-CoV-2 infection by facilitating viral entry
por: Kim, Yeeun, et al.
Publicado: (2022)

Targeting Spike Glycans to Inhibit SARS-CoV2 Viral Entry
por: Guseman, Alex J., et al.
Publicado: (2022)

Targeting spike glycans to inhibit SARS-CoV2 viral entry
por: Guseman, Alex J., et al.
Publicado: (2023)

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
por: Zhou, Hao, et al.
Publicado: (2022)

Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry
por: Guo, Ying, et al.
Publicado: (2009)

Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry
por: Xu, Chuan, et al.
Publicado: (2021)

Preparation of SARS-CoV-2 VLP to study viral assembly, egress, and entry
por: Petersen, Jennifer D., et al.
Publicado: (2022)

SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation
por: Sanders, David W, et al.
Publicado: (2021)

An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research
por: Yang, Peng, et al.
Publicado: (2021)

Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry
por: Zu, Shulong, et al.
Publicado: (2021)

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective
por: Risener, Caitlin J., et al.
Publicado: (2023)

Herbal Compounds Dauricine and Isoliensinine Impede SARS-CoV-2 Viral Entry
por: Dabrell, Shaneek Natoya, et al.
Publicado: (2023)

Highlight of potential impact of new viral genotypes of SARS-CoV-2 on vaccines and anti-viral therapeutics
por: Ghorbani, Abozar, et al.
Publicado: (2022)

Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
por: Mannar, Dhiraj, et al.
Publicado: (2021)

In silico study of the inhibition of SARS-COV-2 viral cell entry by neem tree extracts
por: Shadrack, Daniel M., et al.
Publicado: (2021)

Understanding Activation and Inhibition of SARS-CoV-2 Viral Entry with Single-Virus Microscopy
por: Sengar, Anjali, et al.
Publicado: (2021)

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
por: Kastenhuber, Edward R, et al.
Publicado: (2022)

Abstract 1509: Targeting Spike Glycans to Inhibit SARS-CoV-2 Viral Entry
por: Guseman, Alex, et al.
Publicado: (2023)

Hepatitis C Virus entry: the early steps in the viral replication cycle
por: Sabahi, Ali
Publicado: (2009)

Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections
por: Al-Horani, Rami A.
Publicado: (2020)

HBV Life Cycle: Entry and Morphogenesis
por: Schädler, Stephanie, et al.
Publicado: (2009)

First Therapeutic Approval for Eosinophilic Esophagitis
por: Al-Horani, Rami A., et al.
Publicado: (2022)

Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine
por: Tan, Rebecca Shu Ling, et al.
Publicado: (2022)

Targeting the entry step of SARS-CoV-2: a promising therapeutic approach
por: Li, Jing, et al.
Publicado: (2020)

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
por: Hu, Jie, et al.
Publicado: (2020)

Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication
por: Chen, Jennifer S., et al.
Publicado: (2020)

SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry
por: Huang, I-Chueh, et al.
Publicado: (2006)

Sex differences in viral entry protein expression and host transcript responses to SARS-CoV-2
por: Sun, Mengying, et al.
Publicado: (2020)

SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis
por: Bayati, Armin, et al.
Publicado: (2021)

Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin
por: Du, Xiaohong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5hqvu5n7nec206k64g9kn6cirm